-
Cumberland Pharmaceuticals to sell commercial unit to Apotex for $100 million
-
Cumberland Pharmaceuticals gets FDA approval for expanded Caldolor indication
-
Cumberland Pharmaceuticals (CPIX) Reports Q3 Loss of $0.06
-
Cumberland Pharmaceuticals partners with RedHill for Talicia commercialization
-
Cumberland Pharmaceuticals gets Mexico approval for injectable ibuprofen
-
Cumberland Pharmaceuticals (CPIX) Reports Q2 Loss of $0.02
-
Cumberland Pharmaceuticals secures Vizient contract for Vibativ antibiotic
-
Cumberland Pharmaceuticals (CPIX) Shares Phase 2 FIGHT DMD Trial Results
-
Cumberland Pharmaceuticals (CPIX) announces results from study on Caldolor
-
Cumberland Pharmaceuticals (CPIX) Reports Q1 EPS of $0.16
-
Cumberland Pharmaceuticals (CPIX) Reports Q4 Loss of $0.14
-
Cumberland Pharmaceuticals (CPIX) Announces Results from the Phase 2 FIGHT DMD Trial
-
Cumberland Pharmaceuticals (CPIX): FDA Approves Acetadote SNDA
-
Cumberland Pharmaceuticals (CPIX) Reports Q3 Loss of $0.11
-
Cumberland Pharmaceuticals (CPIX) Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Ifetroban
-
Cumberland Pharmaceuticals (CPIX) Reports Q2 EPS of $0.01

